Key facts
- ProteoWise’s last known valuation is $18.0M (Dec 2024).
- It has raised $11.8M across 3 recorded rounds; the latest was Seed Round ($2.3M) in Dec 2024.
- Notable investors include Connecticut Innovations, Foothill Ventures, Co-Win Ventures, UniWill Ventures, Taihill Venture — 7 tracked in total.
- ProteoWise has filed 3 Form Ds with the SEC since 2020, most recently Dec 2024 ($2.3M sold to 6 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for ProteoWise
Funding rounds
3 roundsAbout ProteoWise
Developer of proteomics instruments designed to enable researchers to analyze proteins easily and efficiently. The company offers proteomic technology that is fast, compact, cost-effective, and yields more data per sample, enabling researchers to finally move beyond blot and into easy, high-throughput bench-top proteomics.
- Sector
- Healthcare
- HQ
- New Haven, CT, United States
- Founded
- 2018
- Employees
- 12
- Website
- proteowise.com/
- Ownership
- Privately Held (backing)
ProteoWise doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ProteoWise shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ProteoWise in its N-PORT filings yet. We sweep new filings monthly.